Is AEON Biopharma, Inc. (AEON) a Buy, Sell, or Hold?
AMEX : AEON
AEON Biopharma, Inc.
$0.286 USD
$0.01 (3.21%)
- Volume
- 222.19K
- Average Volume
- 940.66K
- Market Capitalization
- $7.24M
- P/E Ratio
- -0.06
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.45
- Year Low
- $0.22
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.99
Company Overview
AMEX
Robert Bancroft
Biotechnology
Healthcare
AEON
8
US
USD
Liquidity Metrics
-0.16
0.99
0.99
0.94
0.00
Sales & Valuation
-$
0.00
-0.21
-0.60
-0.99
Profitability
-$3.95
-$39.22M
0.00%
0.00%
223.66%
-696.52%
P/E Metrics
-0.06
0.00
0.00
Analyst Price Target & Rating
2/5
2 Analysts
%
Financial Health Scores
-87.37
2/9
-$44000.0
$8.63M
$25.38M
-$24.15M
Key Metrics (TTM)
$3.39M
0.00
-0.14
0.99
223.66%
-823.75%
-1791.90%
-171.65%
-28451 days
Company Executives
| Name | Title |
|---|---|
| Alex Wilson | Chief Legal & Strategy Officer and Corporate Secretary |
| Robert Bancroft | President, Chief Executive Officer & Director |
| Chad K. Oh | Chief Medical Officer |
| John A. Bencich | Chief Financial Officer |
| Jennifer Sy | Chief Accounting Officer |
Poll Results
No votes yet today — be the first to share your view!
About AEON Biopharma, Inc. (AMEX:AEON) Stock
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California. ...
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
2026-08-03 16:15:00
ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced that it has received written notice from NYSE American LLC (“NYSE American”) confirming that AEON has regained compliance with NYSE American's continued listing standards relating to stockholders' equity.
Bitget Launchpool adds AEON (AEON) with 1.1M in Token Rewards
2026-07-27 07:52:00
VICTORIA, Seychelles, July 27, 2026 (GLOBE NEWSWIRE) -- Bitget , the world's largest Universal Exchange (UEX), announced the addition of AEON (AEON) to Bitget Launchpool and spot market. Spot trading for the AEON/USDT pair opens on July 27, 2026, 11:00 (UTC), with withdrawals available from July 28, 2026, 12:00 (UTC).
2026-07-14 08:00:00
$13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offering $13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offering
2026-06-04 07:00:00
IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the presentation of new analytical and functional data supporting biosimilarity of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society (“AHS”), being held June 4-7, 2026 in Orlando, Florida. The poster is being presented by Chad K. Oh, M.D., AEON's Chief Medical Officer.
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-14 16:05:00
- Reported positive FDA Type 2a meeting supporting ABP-450's comparative analytical strategy under the 351(k) regulatory pathway - - Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90% - - Bolstered leadership team with appointment of John Bencich as Chief Financial Officer - IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, reported today its financial results for the first quarter ended March 31, 2026, and provided a corporate update.
Frequently Asked Questions
-
What is the current AEON Biopharma, Inc. (AEON) stock price?
-
AEON Biopharma, Inc.(AMEX:AEON) stock price is $0.286 in the last trading session. During the trading session, AEON stock reached the peak price of $1.45 while $0.222 was the lowest point it dropped to. The percentage change in AEON stock occurred in the recent session was 3.21% while the dollar amount for the price change in AEON stock was $0.01.
-
AEON's industry and sector of operation?
-
The AMEX listed AEON is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AEON?
-
Alex Wilson | Chief Legal & Strategy Officer and Corporate Secretary
Robert Bancroft | President, Chief Executive Officer & Director
Chad K. Oh | Chief Medical Officer
John A. Bencich | Chief Financial Officer
Jennifer Sy | Chief Accounting Officer -
How many employees does AEON have?
-
Number of AEON employees currently stands at 8. AEON operates from 5 Park Plaza, Irvine, CA 92614, US.
-
Link for AEON official website?
-
Official Website of AEON is: http://www.aeonbiopharma.com
-
How do I contact AEON?
-
AEON could be contacted at phone #949-354-6499 and can also be accessed through its website. AEON operates from 5 Park Plaza, Irvine, CA 92614, US.
-
How many shares of AEON are traded daily?
-
The average number of AEON shares traded daily for last 3 months was 940.66K.
-
What is the market cap of AEON currently?
-
The market value of AEON currently stands at $7.24M with its latest stock price at $0.286